November 2022 Issue Table Of Contents

From The Editor

• Channeling, Or Cancelling, Jack Welch

Feature Articles

• Managing Through Mixed Trial Results And An Economic Downturn

CEO Corner

• The Model Of A Well-Funded Biotech Startup

Companies To Watch

• iTolerance

Industry Research

• Preferred Provider Agreements At Small & Emerging Sponsors

Podcast Summary

• Cashing In On Collaboration

Inside The Industry

• 5 Steps To Avoid Mismanaging Biopharma Grant Funds
• Pioneering In-House, Continuous Manufacturing
• Fueling A Focused Drug Development Model
• 5 Specifications That The FDA's Diversity Plan Needs To Include
• Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising
• Are You Really Fostering A Truly Inclusive Environment?
• From No Experience To A New Career In Biopharma
• 4 Strategies For Overcoming Talent Scarcity In Life Sciences
• New Biotech Startups Poised To Transform Pet Healthcare

Industry Leader

• Can We Accelerate Biosimilars Development Without Compromising Quality Or Safety?
• My Path From The Clinic, To Research, To Biotech Leadership

Leadership Lessons

• Move Beyond Strength To Motivation

Ask The Board

• What Do Corporate Diversity, Equity, And Inclusion (DE&I) Programs Most Often Get Wrong? How Could They Be Improved?
• How Can Leaders Keep Employees Motivated And Focused On Long-Term Objectives In The Context Of Difficult Market Conditions And Short-Term Belt Tightening?